These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1059 related articles for article (PubMed ID: 30529387)

  • 1. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
    Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
    J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
    Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
    J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial.
    Peng Z; Fan W; Liu Z; Xiao H; Wu J; Tang R; Tu J; Qiao L; Huang F; Xie W; Zhuang W; Guo W; Li S; Hua Y; Shen S; He Q; Li D; Li J; Kuang M
    JAMA Surg; 2024 Jun; 159(6):616-624. PubMed ID: 38568599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
    Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Yokosuka O; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y;
    Gut; 2020 Aug; 69(8):1492-1501. PubMed ID: 31801872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis.
    Jin PP; Shao SY; Wu WT; Zhao XY; Huang BF; Fu QH; Que RS; Hu QD
    Jpn J Clin Oncol; 2018 Dec; 48(12):1058-1069. PubMed ID: 30272196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes.
    Xie Y; Tian H; Xiang B; Zhang Y; Liu J; Cai Z; Xiang H
    Medicine (Baltimore); 2021 Aug; 100(33):e26958. PubMed ID: 34414963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.
    Fan W; Zhu B; Chen S; Wu Y; Zhao X; Qiao L; Huang Z; Tang R; Chen J; Lau WY; Chen M; Li J; Kuang M; Peng Z
    JAMA Oncol; 2024 Aug; 10(8):1047-1054. PubMed ID: 38900435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
    Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
    Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
    Liu KC; Hao YH; Lv WF; Jia WD; Ji CS; Zhou CZ; Cheng DL; Xu SB; Gao ZG; Su MX; Shi CS
    Drug Des Devel Ther; 2020; 14():3461-3468. PubMed ID: 32904650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
    Sato Y; Nishiofuku H; Yasumoto T; Nakatsuka A; Matsuo K; Kodama Y; Okubo H; Abo D; Takaki H; Inaba Y; Yamakado K
    J Vasc Interv Radiol; 2018 Aug; 29(8):1061-1067. PubMed ID: 29934260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
    Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
    Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
    Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
    J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.